Glucokinase Activator for Treatment-Resistant Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes, particularly treatment-resistant cases, fail to adequately manage blood glucose levels due to progressive beta cell failure and insulin resistance, necessitating the development of new therapeutic approaches.
Innovation Solution
Administering a therapeutically effective amount of a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor, to enhance glucose regulation and improve glycemic control in subjects with untreated or treatment-resistant diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diabetes treatments (metformin, sulfonylurea, glucose-lowering agents) are used in combination, then glycemic control is improved, but treatment resistance develops and beta cell function progressively fails
Solution Approach 1:
The patent activates glucokinase enzyme to change the metabolic parameter of glucose phosphorylation rate, thereby improving glycemic control through a different biochemical pathway than conventional drugs. This parameter change in enzyme activity provides sustained effectiveness without the progressive treatment resistance seen with traditional agents.
2Reliability
If glucokinase activator is administered, then insulin secretion and glucose balance are improved, but the mechanism differs from approved therapies
Solution Approach 1:
The glucokinase activator serves as a molecular intermediary that enhances the natural glucose-sensing mechanism of beta cells. By acting through this intermediary enzyme activation rather than directly stimulating insulin release like sulfonylureas, the therapy achieves improved insulin secretion while maintaining compatibility with existing treatment protocols through additive effects.
3Quantity of substance
If multiple glucose-lowering agents are combined, then blood glucose levels are reduced, but treatment complexity and potential adverse effects increase
Solution Approach 1:
The glucokinase activator performs multiple functions simultaneously: it enhances insulin secretion from beta cells, improves glucose uptake in peripheral tissues, and suppresses hepatic glucose production. This multi-functionality achieves comprehensive blood glucose reduction through a single agent, thereby reducing treatment regimen complexity compared to combining multiple glucose-lowering agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of a glucokinase activator and a dipeptidyl peptidase-4 inhibitor effectively treats and prevents symptoms of diabetes by improving insulin secretion and glucose balance, offering a new approach for managing treatment-resistant diabetes.
Implementation Method 1
Glucokinase (GK) plays a central role in stabilizing the blood glucose balance in human body. GK as a glucose sensor in glucose homeostasis, regulates the secretion of glucagon, insulin, and GLP-1 stimulated by glucose.
Data Source
AI summary
Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.